Tyrosine kinase inhibitorFDA-approvedSecond-line
Lorbrena
Generic name: lorlatinib
How it works
Blocks the activity of a specific enzyme that helps cancer cells grow and multiply.
Cancer types
Lung Cancer— ALK-positive
Efficacy
In clinical trials, patients with ALK-positive non-small cell lung cancer treated with lorlatinib had a response rate of approximately 76%.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Evaluating Lorlatinib as a First-line Treatment for ALK-positive Lung Cancer in Chinese Adults | Lung Cancer | preclinical | — | Source → |
| Testing Lorlatinib with Local Consolidation Therapy for Advanced Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Lorlatinib Cost-Effective for Lung Cancer Patients in Italy | Lung Cancer | phase-3 | Lorlatinib provided higher benefits (+2.01 life-years; +1.66 quality-adjusted life-years) at lower costs (-€19,210 per patient) compared to alectinib. | Source → |
| Rare Side Effects Found in Lung Cancer Treatment | Lung Cancer | observational | — | Source → |
| Lorlatinib Linked to Rare but Specific Neuropsychiatric Side Effects | Lung Cancer | observational | — | Source → |
| Lorlatinib Shows Promise in Lung Cancer Patients Who Have Tried Other Treatments | Lung Cancer | preclinical | The objective response rate was 42% (95% CI, 31%-55%). | Source → |
| Lorlatinib Efficacy and Safety in Lung Cancer Patients | Lung Cancer | observational | The objective response rate was 82.9% in the first-line treatment cohort, and the disease control rate was 100%. The median progression-free survival had not yet been reached in the first-line treatment cohort, and the median progression-free survival was 16.8 months in the subsequent-line treatment cohort. | Source → |
| Lorlatinib Shows Promise in Lung Cancer Patients Who Failed Earlier Treatments | Lung Cancer | observational | The overall objective response rate was 64.6%, with the disease control rate of 96.3%. | Source → |
| New Lung Cancer Treatments Show Promise but Raise Concerns | Lung Cancer | phase-3 | — | Source → |
| Lorlatinib Linked to Higher Heart Risks in Lung Cancer Patients | Lung Cancer | observational | — | Source → |
| Weight Gain Risk for Lung Cancer Patients on Lorlatinib | Lung Cancer | observational | Patients receiving lorlatinib experienced significantly higher maximum weight gain (mean 13.5% [95% confidence interval 10.8-16.2]) | Source → |
| Lorlatinib Monotherapy Shows Promise for Rare Lung Cancer | Lung Cancer | observational | — | Source → |
| Lorlatinib Therapy Linked to Unusual Lipid Levels | Lung Cancer | observational | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.